公开(公告)号：US20230257479A1

公开(公告)日：2023-08-17

申请号：US17642488

申请日：2020-09-11

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C.W. BREIJ ,  Bart E.C.G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN ,  Reshma Abdulla RANGWALA ,  Sri GHATTA ,  Ruud BRAKENHOFF ,  Rieneke VAN DE VEN

IPC: C07K16/30 ,  A61P35/00 ,  A61P1/00

CPC classification number: C07K16/30 ,  A61P1/00 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

公开(公告)号：US20230076417A1

公开(公告)日：2023-03-09

申请号：US17714735

申请日：2022-04-06

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Joost MELIS ,  Tom VINK ,  Hendrik TEN NAPEL ,  Esther BREIJ ,  David SATIJN ,  Paul PARREN

IPC: C07K16/32 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention relates to a multispecific antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain. The first domain specifically binds a target molecule (T), and the second domain specifically binds an internalizing effector protein (E), the second antigen-binding domain having a dissociation constant (KD) with E of between 10−9 and 10−8 M. The multispecific antigen-binding molecule is useful in a method for treating and/or preventing a cancer.

公开(公告)号：US20220324980A1

公开(公告)日：2022-10-13

申请号：US17695550

申请日：2022-03-15

Applicant: GENMAB A/S

Inventor： Louise KOOPMAN ,  Patrick ENGELBERTS ,  Dennis VERZIJL ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Sieto BOSGRA ,  Frederikke L. EGEROD ,  David SATIJN ,  Esther C. W BREIJ

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20220169738A1

公开(公告)日：2022-06-02

申请号：US17369542

申请日：2021-07-07

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20210122830A1

公开(公告)日：2021-04-29

申请号：US17003442

申请日：2020-08-26

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Edward N. VAN DEN BRINK ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD, D.M.Sc. ,  David SATIJN ,  Jan VAN DE WINKEL ,  Paul PARREN

IPC: C07K16/30 ,  C07K16/32

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20160067349A1

公开(公告)日：2016-03-10

申请号：US14854613

申请日：2015-09-15

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: A61K47/48 ,  C07K16/30 ,  A61K45/06

CPC classification number: A61K47/48561 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/30 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.

Abstract translation: 针对组织因子的抗体药物偶联物。 还公开了包含抗体和抗体药物共轭物的药物组合物，以及使用抗体和抗体药物偶联物的治疗和诊断方法。

公开(公告)号：US20240254252A1

公开(公告)日：2024-08-01

申请号：US17259342

申请日：2019-07-15

Applicant: GENMAB A/S

Inventor： Bart E. C. G. DE GOEIJ ,  Grietje ANDRINGA ,  Frank BEURSKENS ,  Janine SCHUURMAN ,  David SATIJN ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/02 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.

公开(公告)号：US20240228641A9

公开(公告)日：2024-07-11

申请号：US18478711

申请日：2023-09-29

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20240132607A1

公开(公告)日：2024-04-25

申请号：US18478711

申请日：2023-09-28

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20230321261A1

公开(公告)日：2023-10-12

申请号：US17957302

申请日：2022-09-30

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  A61K45/06

CPC classification number: A61K47/6803 ,  A61K39/001102 ,  A61K45/06 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61P35/00 ,  C07K16/2863 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.